The European Commission has reached an agreement with the pharmaceutical company Gilead Sciences to buy 500 thousand doses of remdesivir antiviral, used to treat patients who have contracted the new coronavirus (Sars-CoV-2).
The value of the negotiation was 70 million euros, which comes from the Emergency Support Instrument (ESI).
Currently, the drug is the only one approved by the European Union to be used in patients with Covid-19, who are over 12 years old and who need to use mechanical breathing. The medication was authorized in early July, after release from the European Medicines Agency (EMA).
In addition to the 27 member countries of the bloc, the purchase also includes the United Kingdom, the European Economic Area (EEA) states and six candidate nations to enter the bloc (Albania, North Macedonia, Montenegro, Serbia, Kosovo and Bosnia and Herzegovina )
Read more in Portuguese at Istoé